logo
logo

Viome Life Sciences Raises $54M To Accelerate Development Of Its Mrna Platform For Prevention, Diagnosis, And Therapeutics For Chronic Disorders, Cancers, And Aging

Nov 10, 2021•almost 4 years ago

Amount Raised

$54 Million

Bellevue

Description

Viome Life Sciences, a mission-driven systems biology company aiming to help individuals improve their health, today announces its raise of $54M in a pre-series C convertible funding with participation from existing investors and new investors. This raise follows a $56M series B round announced in November 2019, bringing Viome's total funds raised to date to over $125M.

Company Information

Company

Viome Life Sciences

Location

Bellevue, Washington, United States

About

Viome Life Sciences is a mission-driven systems biology company founded in 2016 to tackle the epidemic of chronic diseases, cancer, and aging. To help individuals improve their health and to better understand the root of chronic diseases, Viome is strategically split into two divisions. Viome Consumer Services is focused on growing its established consumer products including tests, nutrition plans, and supplements. Viome Health Sciences is devoted to advancing its precision diagnostics and therapeutics platform. By conducting mRNA analysis at a mass scale, Viome is digitizing human biology and ultimately stopping the onset and progression of chronic diseases. Recently, Viome garnered FDA Approval for its unique mRNA technology and AI platform to detect cancers and has already successfully developed over 30 predictive models for some of the most prominent chronic diseases. For more information, visit https://www.viomelifesciences.com/

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech